Ceftazidime for Typhoid Fever
Ceftazidime is NOT recommended for treating typhoid fever; use ceftriaxone (a third-generation cephalosporin) instead, as it is the evidence-based cephalosporin of choice for enteric fever, particularly in quinolone-resistant cases. 1
Why Ceftriaxone, Not Ceftazidime
Guideline-Recommended Cephalosporin
WHO guidelines specifically recommend ceftriaxone (not ceftazidime) as the second-line treatment for typhoid fever when fluoroquinolones fail or in quinolone-resistant cases. 1
The 2012 WHO guidelines for treatment of typhoid fever in children list third-generation cephalosporins (e.g., ceftriaxone) as second-line therapy, with no mention of ceftazidime for this indication. 1
For quinolone-resistant Salmonella typhi, WHO 2003 guidelines recommend azithromycin or ceftriaxone as first-line options, with cefixime as an alternative. 1
Clinical Evidence Supports Ceftriaxone
Ceftriaxone demonstrated lower risk of treatment failure compared to the fluoroquinolone gatifloxacin in culture-confirmed enteric fever (HR 0.24,95% CI 0.08-0.73). 1
A 2022 Cochrane review found that ceftriaxone may result in decreased clinical failure compared to azithromycin (RR 0.42,95% CI 0.11 to 1.57) and shorter time to defervescence compared to azithromycin (mean difference -0.52 days). 2
The same review concluded that ceftriaxone is an effective treatment for adults and children with enteric fever, with few adverse effects. 2
Ceftazidime Lacks Evidence for Typhoid
No clinical trials or guidelines support ceftazidime use for typhoid fever treatment. 1
The FDA label for ceftazidime lists approved indications including urinary tract infections, pneumonia, skin infections, bone/joint infections, gynecologic infections, intra-abdominal infections, and meningitis—but NOT enteric fever or typhoid. 3
While ceftazidime has activity against some Salmonella species in vitro, clinical efficacy has not been established in adequate and well-controlled trials for typhoid fever. 3
Recommended Treatment Algorithm for Typhoid Fever
First-Line Options (Based on Susceptibility)
Fully susceptible strains: Fluoroquinolone (ciprofloxacin, ofloxacin, or gatifloxacin). 1
Multidrug-resistant (MDR) strains: Fluoroquinolone or cefixime as first-line; azithromycin or cefixime as alternatives. 1
Second-Line Options (Quinolone-Resistant or Treatment Failure)
Azithromycin (20 mg/kg/day for 7-14 days): Demonstrated lower clinical failure rates (OR 0.48) and shorter hospital stays compared to fluoroquinolones, plus lower relapse rates compared to ceftriaxone. 1
Ceftriaxone (2 grams IV every 8 hours for adults; 50-75 mg/kg/day for children): Effective for quinolone-resistant cases with good CNS penetration if complications develop. 1, 2
Cefixime (oral alternative): 400 mg twice daily for adults, though may have higher failure rates than fluoroquinolones (RR 13.39). 1, 2
Extensively Drug-Resistant (XDR) Strains
For XDR typhoid (resistant to fluoroquinolones, third-generation cephalosporins, and macrolides), azithromycin or carbapenems may be required based on susceptibility testing. 4
The ongoing XDR outbreak in Pakistan since 2016 necessitates culture and susceptibility testing to guide therapy. 4
Critical Clinical Pitfalls
Do not use ceftazidime interchangeably with ceftriaxone—they are different third-generation cephalosporins with distinct clinical indications and evidence bases. 3, 2
Resistance patterns vary by region: South Asian strains commonly show nalidixic acid resistance (>90% in some studies), making fluoroquinolones less effective despite in vitro susceptibility. 5
Treatment duration matters: Azithromycin requires 7-14 days, ceftriaxone typically 10-14 days, and fluoroquinolones 7-14 days depending on clinical response. 2, 5
Monitor for complications: Intestinal perforation, encephalopathy, myocarditis, and bone/joint infections may require longer treatment courses and surgical intervention. 4